Novavax (NVAX) Reports Q4 EPS of ($11.28), Guides 2022 Revenue of $4-$5B
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $8.14 --0%
Financial Fact:
Basic and diluted net loss per share: -0.24
Today's EPS Names:
EGRX, MOVE, MDRX, More
Financial Fact:
Basic and diluted net loss per share: -0.24
Today's EPS Names:
EGRX, MOVE, MDRX, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($11.28), $10.73 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $222 million versus the consensus estimate of $442.77 million.
GUIDANCE:
Novavax sees FY2022 revenue of $4-5 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c
- Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
Create E-mail Alert Related Categories
Corporate News, Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
